Treatment of Diamond - Blackfan Anemia With Recombinant Human Interleukin
نویسندگان
چکیده
This report describes the response of eighteen DiamondBlackfan anemia (DBA) patients to recombinant human interleukin-3 (rhlL-3). rhlL-3 was administered subcutaneously once daily on an escalating dose schedule (0.5 to 10 pg/kg/d). The rhlL-3 dose was escalated every 21 days until erythroid response was attained, grade 111 or IV nonhematologic toxicity was observed, or the maximum rhlL-3 dose was reached. Four patients experienced clinically significant erythroid responses. Two of the responders were steroid-dependent and transfusion-independent, while two were steroid-independent and transfusion-dependent. Baseline clinical or laboratory parameters, in particu-
منابع مشابه
Diamond-Blackfan anemia: promotion of marrow erythropoiesis in vitro by recombinant interleukin-3.
To clarify the defective erythropoiesis in eight patients with Diamond-Blackfan anemia, we studied their bone marrow response in vitro to recombinant human interleukin-3 (IL-3) and recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). In an erythropoietin-containing assay system, specimens from six of the eight patients yielded low numbers of erythroid colonies compared to cont...
متن کاملDiamond-Blackfan Anemia: Promotion of Marrow Erythropoiesis In Vitro
To clarify the defective erythropoiesis in eight patients with Diamond-Blackfan anemia. we studied their bone marrow response in vitro to recombinant human interleukin-3 (11-3) and recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF). In an erythropoietincontaining assay system. specimens from six of the eight patients yielded low numbers of erythroid colonies compared to contr...
متن کاملTreatment of Diamond-Blackfan anemia with recombinant human interleukin-3.
This report describes the response of eighteen Diamond-Blackfan anemia (DBA) patients to recombinant human interleukin-3 (rhIL-3). rhIL-3 was administered subcutaneously once daily on an escalating dose schedule (0.5 to 10 micrograms/kg/d). The rhIL-3 dose was escalated every 21 days until erythroid response was attained, grade III or IV nonhematologic toxicity was observed, or the maximum rhIL...
متن کاملDiamond-Blackfan anemia: heterogenous response of hematopoietic progenitor cells in vitro to the protein product of the steel locus.
Diamond-Blackfan anemia is a congenital disorder of erythropoiesis in humans, characterized by a macrocytic anemia often associated with physical anomalies. Mutations at either the W or Steel loci in the mouse also leads to a severe macrocytic anemia, as well as other developmental abnormalities. The W locus encodes the proto-oncogene c-kit, a member of the receptor tyrosine kinase family, whil...
متن کاملInterleukin-2-induced graft-versus-leukemia for the treatment of AML in a BRCA2 Fanconi anemia patient.
Biallelic BRCA2 mutations occur in 2% of patients with Fanconi anemia and are associated with a high risk of acute leukemia at an early age and a poor prognosis. For the first time, we report the use of interleukin-2 to stimulate a graft-versus-leukemia effect and induce complete remission in a patient with BRCA2 Fanconi anemia and refractory acute myelogenous leukemia, suggesting the potential...
متن کامل